§ 32.21. Radioactive drug: Manufacture, preparation, or transfer for commercial distribution of capsules containing carbon-14 urea each for “in vivo” diagnostic use for humans to persons exempt from licensing; Requirements for a license.
289 words·~1 min read·
/us/cfr/t10/s§ 32.21·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)An application for a specific license to manufacture, prepare, process, produce, package, repackage, or transfer for commercial distribution capsules containing 37 kBq (1 µCi) carbon-14 urea (allowing for nominal variation that may occur during the manufacturing process) each for “in vivo” diagnostic use, to persons exempt from licensing under § 30.21 of this chapter or the equivalent regulations of an Agreement State will be approved if:
(1)The applicant satisfies the general requirements specified in § 30.33 of this chapter, provided that the requirements of § 30.33(a)
(2)and
(3)of this chapter do not apply to an application for a license to transfer byproduct material manufactured, prepared, processed, produced, packaged, or repackaged pursuant to a license issued by an Agreement State;
(2)The applicant meets the requirements under § 32.72(a)(2) of this part;
(3)The applicant provides evidence that each capsule contains 37 kBq (1 µCi) carbon-14 urea (allowing for nominal variation that may occur during the manufacturing process);
(4)The carbon-14 urea is not contained in any food, beverage, cosmetic, drug (except as described in this section) or other commodity designed for ingestion or inhalation by, or topical application to, a human being;
(5)The carbon-14 urea is in the form of a capsule, identified as radioactive, and to be used for its radioactive properties, but is not incorporated into any manufactured or assembled commodity, product, or device intended for commercial distribution; and
(6)The applicant submits copies of prototype labels and brochures and the NRC approves these labels and brochures.
(b)Nothing in this section relieves the licensee from complying with applicable FDA, other Federal, and State requirements governing drugs. [62 FR 63640, Dec. 2, 1997, as amended at 66 FR 64738, Dec. 14, 2001]